Alpha 2.0
Login Register
» Authors » Phillip Read

Phillip Read

Explore the profile of Phillip Read including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 72
Citations 934
Followers 0
Related Specialties
Infectious Diseases
Psychiatry
Public Health
Top 10 Co-Authors
Gregory J Dore
Jason Grebely
Marianne Martinello
Janaki Amin
Anna McNulty
Heather Valerio
Philippa Marks
Gail V Matthews
Charles Henderson
Behzad Hajarizadeh
Published In
Sex Health
Int J Drug Policy
Clin Infect Dis
J Viral Hepat
Drug Alcohol Rev
Affiliations
Soon will be listed here.
Recent Articles
1.
Control and Elimination of Hepatitis C Virus Among People With HIV in Australia: Extended Follow-up of the CEASE Cohort (2014-2023)
Martinello M, Carson J, Post J, Finlayson R, Baker D, Read P, et al.
Open Forum Infect Dis . 2024 Dec; 11(12):ofae665. PMID: 39691290
Background: Approximately 10% of people with HIV in Australia had active hepatitis C virus (HCV) infection prior to availability of government-subsidized direct-acting antiviral (DAA) therapy in 2016. This analysis evaluated...
2.
Syphilis testing, incidence, and reinfection among gay and bisexual men in Australia over a decade spanning HIV PrEP implementation: an analysis of surveillance data from 2012 to 2022
Traeger M, Guy R, Taunton C, Chow E, Asselin J, Carter A, et al.
Lancet Reg Health West Pac . 2024 Sep; 51:101175. PMID: 39263009
Background: Gay and bisexual men (GBM) remain overrepresented among syphilis diagnoses in Australia and globally. The extent to which changes in sexual networks associated with HIV pre-exposure prophylaxis (PrEP) and...
3.
Coverage of cervical cancer prevention interventions among people in Australia who inject drugs
Price O, Machalek D, Sutherland R, Gibbs D, Colledge-Frisby S, Read P, et al.
Int J Drug Policy . 2024 Aug; 132:104566. PMID: 39173252
Background: The human papillomavirus (HPV) vaccine and regular (i.e., every five years) cervical screening are essential to prevent cervical cancer. Australia has high overall coverage of both interventions but little...
4.
Hepatitis C (HCV) Reinfection and Risk Factors among Clients of a Low-Threshold Primary Healthcare Service for People Who Inject Drugs in Sydney, Australia
Read P, Tang B, Silins E, Doab A, Cornelisse V, Gilliver R
Viruses . 2024 Jun; 16(6). PMID: 38932249
Hepatitis C (HCV) reinfection studies have not focused on primary healthcare services in Australia, where priority populations including people who inject drugs (PWID) typically engage in healthcare. We aimed to...
5.
Critical Success Factors for Intersectoral Collaboration: Homelessness and COVID-19 - Case Studies and Learnings from an Australian City
Macfarlane S, Haigh F, Woodland L, Goodger B, Larkin M, Miller E, et al.
Int J Integr Care . 2024 Jun; 24(2):19. PMID: 38828122
Introduction: The COVID-19 pandemic disproportionally impacted people experiencing homelessness, including people sleeping rough, people in temporary accommodation and those living in boarding houses. This paper reports on intersectoral responses across...
6.
Factors associated with experiencing stigma, discrimination, and negative health care treatment among people who inject drugs
Broady T, Valerio H, Alavi M, Wheeler A, Silk D, Martinello M, et al.
Int J Drug Policy . 2024 May; 128:104468. PMID: 38795465
Introduction: Stigma has negative consequences for the health of people who inject drugs and people living with hepatitis C virus (HCV). This study evaluated factors associated with stigma related to...
7.
Sex and gender differences in hepatitis C virus risk, prevention, and cascade of care in people who inject drugs: systematic review and meta-analysis
Levinsson A, Zolopa C, Vakili F, Udhesister S, Kronfli N, Maheu-Giroux M, et al.
EClinicalMedicine . 2024 Apr; 72:102596. PMID: 38633576
Background: People who inject drugs (PWID) are a priority population in HCV elimination programming. Overcoming sex and gender disparities in HCV risk, prevention, and the cascade of care is likely...
8.
Needle and syringe sharing among people who have recently injected drugs in Australia: The ETHOS Engage Study
Farooq A, Valerio H, Wheeler A, Martinello M, Henderson C, Silk D, et al.
Drug Alcohol Rev . 2024 Apr; 43(4):1019-1028. PMID: 38630939
Introduction: Understanding needle/syringe sharing is crucial for reducing hepatitis C virus (HCV) infection and reinfection. This study aimed to assess the prevalence and factors associated with needle/syringe sharing among people...
9.
Factors associated with hepatitis C testing, treatment, and current hepatitis C infection among men and women who inject drugs: The ETHOS engage study
Valerio H, Marshall A, Conway A, Treloar C, Carter L, Martinello M, et al.
Int J Drug Policy . 2024 Apr; 127:104394. PMID: 38608357
Background: Evaluating gender-specific trends in hepatitis C virus (HCV) treatment uptake among men and women who inject drugs is crucial for ensuring equitable progress towards HCV elimination. This study aimed...
10.
Chlamydia retesting remains low among young women in Australia: an observational study using sentinel surveillance data, 2018-2022
Munari S, Wilkinson A, Asselin J, Owen L, Read P, Finlayson R, et al.
Sex Health . 2024 Feb; 21. PMID: 38369757
Background: Chlamydia remains the most notified bacterial sexually transmissible infection in Australia with guidelines recommending testing for re-infection at 3months post treatment. This paper aimed to determine chlamydia retesting and...